Androgen suppression therapy and prostate cancer

Balancing the harms and the benefits


  • Michael G. Oefelein MD

    Corresponding author
    1. Department of Urology, Case Western Reserve University, Cleveland, Ohio
    • Case Western Reserve University, Department of Urology, 11100 Euclid Avenue, Cleveland, OH 44106
    Search for more papers by this author
    • Fax: (216) 844-7528

  • See referenced original article on pages 3290–7, this issue.


Men with localized, low-risk carcinoma of the prostate with multiple comorbidities may experience few benefits from androgen suppression therapy (AST), and probably would be better served by an active surveillance approach, with delayed AST if evidence of progression develops. A proactive position regarding the potential for AST to unmask existing or occult coronary artery disease or for AST to facilitate development of cardiovascular disease warrants consideration.